Multi-class Classification on Dermatology
98.54F1-scoreIMOVNO+
Evaluation Results
| Method | Links | |||||
|---|---|---|---|---|---|---|
| IMOVNO+Validation=5-fold cross-validation2026.02 | 98.54 | 98.62 | 98.55 | 98.5 | — | |
| IMOVNO+Binarization=true, Cross-validation=5-fold2026.02 | 98.54 | 98.62 | 98.55 | 98.5 | — | |
| IMOVNO+Evaluation Protocol=5-fold cross-validation2026.02 | 98.54 | — | — | 98.5 | 98.54 | |
| IMOVNO+Strategy=Binarization, Validation=5-fold cross-validation2026.02 | 98.54 | 98.62 | 98.55 | 98.5 | — | |
| DT-E-EVRSEvaluation Protocol=5-fold cross-validation2026.02 | 97.9 | — | — | 97.6 | — | |
| OVO-ISMOTEBinarization=true, Cross-validation=5-fold2026.02 | 97.57 | 97.82 | 97.59 | 97.4 | — | |
| OVO-ISMOTEStrategy=Binarization, Validation=5-fold cross-validation2026.02 | 97.57 | 97.82 | 97.59 | 97.4 | — | |
| SMOTE-CDNNValidation=5-fold cross-validation2026.02 | 96.22 | 96.46 | 96.35 | 96.07 | — | |
| SVM-E-EVRSEvaluation Protocol=5-fold cross-validation2026.02 | 95.2 | — | — | 95.4 | — | |
| OVO-HSCFBinarization=true, Cross-validation=5-fold2026.02 | 94.32 | 95.25 | 94.19 | 93.56 | — | |
| OVO-HSCFStrategy=Binarization, Validation=5-fold cross-validation2026.02 | 94.32 | 95.25 | 94.19 | 93.56 | — | |
| OVO-GDDSADBinarization=true, Cross-validation=5-fold2026.02 | 93.87 | 94.88 | 93.71 | 93.17 | — | |
| OVO-GDDSADStrategy=Binarization, Validation=5-fold cross-validation2026.02 | 93.87 | 94.88 | 93.71 | 93.17 | — | |
| ECDNNValidation=5-fold cross-validation2026.02 | 86.68 | 87.06 | 87.73 | 86.7 | — | |
| SAMME.C2Validation=5-fold cross-validation2026.02 | 39.15 | 37.6 | 47.65 | 3.16 | — |